Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 9, 2013, Pages 2007-2014

  McGovern, Rachel A ^a   Symons, Jori ^b   Poon, Art F Y ^a   Richard Harrigan, P ^a,c   Van Lelyveld, Steven F L ^b   Hoepelman, Andy I M ^b   Van Ham, Petra M ^b   Dong, Winnie ^a   Wensing, Annemarie M J ^b   Nijhuis, Monique ^b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

454 deep sequencing; Dual mixed tropism; Genotyping; V3 loop

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MARAVIROC;

ADD ON THERAPY; ALGORITHM; ARTICLE; BLOOD SAMPLING; CASE REPORT; DRUG EXPOSURE; FITNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; PATIENT SELECTION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TREATMENT FAILURE; TROPISM; VIRUS LOAD;

454 DEEP SEQUENCING; DUAL/MIXED TROPISM; GENOTYPING; V3 LOOP;

ANTI-HIV AGENTS; COHORT STUDIES; CYCLOHEXANES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; SELECTION, GENETIC; TRIAZOLES; VIRAL TROPISM;

EID: 84882589635     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt153     Document Type: Article

References (35)

1. Deng HK, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
2. Feng Y, Broder CC, Kennedy PE et al. HIV-1 entry cofactor: functional cDNA cloning of seven transmembrane, G coupled-protein receptor. Science 1996; 272: 872-6.
3. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIVcoreceptors: roles in viral entry tropism and disease. Ann Rev Immunol 1999; 17: 657-700.
4. Xiao L, Rudolph DL, Owen SM et al. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 1998; 12: F137-43.
5. Schuitemaker H, Koot M, Kootstra NA et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992; 66: 1354-60.
6. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169: 968-74.
7. Berger EA, Doms RW, Fenyo EM et al. A new classification for HIV-1. Nature 1998; 391: 240.
8. Zhang LQ, Huang YX, He T et al. HIV-1 subtype and second-receptor use. Nature 1996; 383: 768.
9. Doranz BJ, Rucker J, Yi Y et al. A dual-tropic primary HIV-1 isolate that uses fusin and the b-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85: 1149-58.
10. Fouchier RAM, Groenink M, Kootstra NA et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66: 3183-7.
11. Cann AJ, Churcher MJ, Boyd M et al. The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J Virol 1992; 66: 305-9.
12. Huang CC, Tang M, Zhang MY et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005; 310: 1025-8.
13. De Jong JJ, De Ronde A, Keulen Wet al. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992; 66: 6777-80.
14. Resch W, Hoffman N, Swanstrom R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virol 2001; 288: 51-62.
15. Low AJ, Dong W, Chan D et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007; 21: F17-24.
16. Lengauer T, Sander O, Sierra S et al. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007; 25: 1407-10.
17. Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-32.
18. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
19. Saag M, Goorich J, Fatkenheuer G et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009; 199: 1638-47.
20. MacArthur RD, Novak RM. Maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008; 47: 236-41.
21. Whitcomb JM, Huang W, Fransen S et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51: 566-75.
22. Reeves JD, Coakley E, Petropolous CJ et al. An enhanced-sensitivity TrofileTM HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry 2009; 3: 94-102.
23. McGovern RA, Thielen A, Mo T et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24: 2517-25.
24. Beerenwinkel N, Daumer M, Oette M et al. Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003; 31: 3850-5.
25. Swenson LC, Mo T, Dong WWY et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 2011; 203: 237-45.
26. Swenson LC, Mo T, Dong WWYet al. Deep V3 sequencing for HIV type 1 tropism in treatment-naïve patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 2011; 53: 732-42.
27. Wang C, Mitsuya Y, Gharizadeh B et al. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 2007; 17: 1195-201.
28. Swenson LC, Moores A, Low AJ et al. Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr 2010; 54: 506-10.
29. Crow JF, Kimura M. An Introduction to Population Genetics Theory. New York, NY: Harper & Row, 1970.
30. Westby M, Lewis M, Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80: 4909-20.
31. Tsibris AMN, Korber B, Arnaout R et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PloS One 2009; 4: e5683.
32. McGovern RA, Poon AFY, Leal M et al. Next generation deep sequencing to evaluate viral tropism in HIV-1 patients exposed to maraviroc add-on therapy for 8 days. In: Abstracts of the Sixth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, 2011. Abstract TUPDA0102, p. 122. International AIDS Society, Geneva, Switzerland.
33. McGovern R, Dong W, Zhong X et al. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naïve patients of the MERIT trial. J Acquir Immune Defic Syndr 2012; 61: 279-86.
34. Vandekerckhove LPR, Wensing AMJ, Kaiser R et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet 2011; 11: 394-407.
35. Jabara CB, Jones CD, Roach J et al. Accurate sampling and deep sequencing of the HIV-1 protease gene using a primer ID. PNAS 2011; 108: 20166-71.